Syndax Begins New Chapter As A Late-Stage Drug Developer
This article was originally published in The Pink Sheet Daily
A recent influx of cash to the small biotech will allow Syndax to develop its oncology asset on its own, beginning with a Phase III trial and potentially continuing to U.S. commercialization.
You may also be interested in...
Epigenetic modifiers are targeting a widening range of indications as growing knowledge of the underlying biology enables improved agents and therapeutic strategies. Nonetheless, issues of selectivity, toxicity, and finding adequate biomarkers still prevent the field from reaching its full potential.
Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.